title: Pyridoxamine as a multifunctional pharmaceutical: targeting pathogenic glycation and oxidative damage.
abstract: The discovery that pyridoxamine (PM) can inhibit glycation reactions and the formation of advanced glycation end products (AGEs) stimulated new interest in this B6 vitamer as a prospective pharmacological agent for treatment of complications of diabetes. The mechanism of action of PM includes: (i) inhibition of AGE formation by blocking oxidative degradation of the Amadori intermediate of the Maillard reaction; (ii) scavenging of toxic carbonyl products of glucose and lipid degradation; and (iii) trapping of reactive oxygen species. The combination of these multiple activities along with PM safety posture it as a promising drug candidate for treatment of diabetic complications as well as other multifactorial chronic conditions in which oxidative reactions and carbonyl compounds confer pathogenicity.
authors.affiliation: Division of Nephrology, Vanderbilt University Medical Center, S-3223 MCN, 1161 21st Avenue South, Nashville, Tennessee 37232-2372, USA. paul.voziyan@vanderbilt.edu
authors.forename: P A
authors.initials: PA
authors.lastname: Voziyan
authors.forename: B G
authors.initials: BG
authors.lastname: Hudson
mesh_terms: D000818:Animals; D048909:Diabetes Complications / Q000188:drug therapy / Q000209:etiology; D017127:Glycation End Products, Advanced / Q000096:biosynthesis*; D006801:Humans; D015416:Maillard Reaction; D018384:Oxidative Stress / Q000187:drug effects*; D011733:Pyridoxamine / Q000737:chemistry / Q000494:pharmacology* / Q000627:therapeutic use; D017382:Reactive Oxygen Species / Q000378:metabolism
chemical_list: D017127:Glycation End Products, Advanced; D017382:Reactive Oxygen Species; D011733:Pyridoxamine